LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

LLY

992.1

+1.45%↑

JNJ

243.48

-0.21%↓

ABBV

224.42

-1.08%↓

NVS

153.89

-0.26%↓

AZN

190.23

-0.59%↓

Search

Sana Biotechnology Inc

Avatud

SektorTervishoid

3.29 8.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.01

Max

3.37

Põhinäitajad

By Trading Economics

Sissetulek

-17M

-59M

Töötajad

142

EBITDA

-11M

-50M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+201.59% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. märts 2026

Turustatistika

By TradingEconomics

Turukapital

-217M

889M

Eelmine avamishind

-4.93

Eelmine sulgemishind

3.29

Uudiste sentiment

By Acuity

50%

50%

153 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Sana Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. märts 2026, 23:12 UTC

Kuumad aktsiad

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12. märts 2026, 22:15 UTC

Tulu

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12. märts 2026, 21:42 UTC

Uudisväärsed sündmused

Stryker Says Cyberattack Disruption Is Continuing

12. märts 2026, 21:29 UTC

Uudisväärsed sündmused

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12. märts 2026, 21:27 UTC

Tulu

Adobe CEO to Depart as AI Boosts Sales -- Update

12. märts 2026, 20:46 UTC

Tulu

Adobe Posts Higher Sales With CEO Set to Depart

12. märts 2026, 20:21 UTC

Uudisväärsed sündmused

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12. märts 2026, 23:57 UTC

Market Talk

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. märts 2026, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12. märts 2026, 22:13 UTC

Tulu

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12. märts 2026, 22:13 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

12. märts 2026, 22:13 UTC

Market Talk
Tulu

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12. märts 2026, 21:16 UTC

Omandamised, ülevõtmised, äriostud

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12. märts 2026, 21:04 UTC

Tulu

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Sales $865M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q Net $558.3M >WPM

12. märts 2026, 21:02 UTC

Tulu

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12. märts 2026, 20:57 UTC

Market Talk
Uudisväärsed sündmused

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12. märts 2026, 20:10 UTC

Tulu

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe 1Q Rev $6.4B >ADBE

12. märts 2026, 20:05 UTC

Tulu

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Võrdlus sarnastega

Hinnamuutus

Sana Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

201.59% tõus

12 kuu keskmine prognoos

Keskmine 9.5 USD  201.59%

Kõrge 12 USD

Madal 7 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Sana Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

5

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.68 / 1.87Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

153 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat